Feasibility Study and Clinical Impact of Incorporating Breast Tissue Density in High-Risk Breast Cancer Screening Assessment
Breast tissue density (BTD) is known to increase the risk of breast cancer but is not routinely used in the risk assessment of the population-based High-Risk Ontario Breast Screening Program (HROBSP). This prospective, IRB-approved study assessed the feasibility and impact of incorporating breast ti...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/29/11/688 |
| _version_ | 1797465607234387968 |
|---|---|
| author | Alison Rusnak Shawna Morrison Erika Smith Valerie Hastings Kelly Anderson Caitlin Aldridge Sari Zelenietz Karen Reddick Sonia Regnier Ellen Alie Nayaar Islam Rutaaba Fasih Susan Peddle Erin Cordeiro Eva Tomiak Jean M. Seely |
| author_facet | Alison Rusnak Shawna Morrison Erika Smith Valerie Hastings Kelly Anderson Caitlin Aldridge Sari Zelenietz Karen Reddick Sonia Regnier Ellen Alie Nayaar Islam Rutaaba Fasih Susan Peddle Erin Cordeiro Eva Tomiak Jean M. Seely |
| author_sort | Alison Rusnak |
| collection | DOAJ |
| description | Breast tissue density (BTD) is known to increase the risk of breast cancer but is not routinely used in the risk assessment of the population-based High-Risk Ontario Breast Screening Program (HROBSP). This prospective, IRB-approved study assessed the feasibility and impact of incorporating breast tissue density (BTD) into the risk assessment of women referred to HROBSP who were not genetic mutation carriers. All consecutive women aged 40–69 years who met criteria for HROBSP assessment and referred to Genetics from 1 December 2020 to 31 July 2021 had their lifetime risk calculated with and without BTD using Tyrer-Cuzick model version 8 (IBISv8) to gauge overall impact. McNemar’s test was performed to compare eligibility with and without density. 140 women were referred, and 1 was excluded (<i>BRCA</i> gene mutation carrier and automatically eligible). Eight of 139 (5.8%) never had a mammogram, while 17/131 (13%) did not have BTD reported on their mammogram and required radiologist review. Of 131 patients, 22 (16.8%) were clinically impacted by incorporation of BTD: 9/131 (6.9%) became eligible for HROBSP, while 13/131 (9.9%) became ineligible (<i>p</i> = 0.394). It was feasible for the Genetics clinic to incorporate BTD for better risk stratification of eligible women. This did not significantly impact the number of eligible women while optimizing the use of high-risk supplemental MRI screening. |
| first_indexed | 2024-03-09T18:24:54Z |
| format | Article |
| id | doaj.art-dee42803ed58435f8e7b4ac738654377 |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-09T18:24:54Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-dee42803ed58435f8e7b4ac7386543772023-11-24T08:03:15ZengMDPI AGCurrent Oncology1198-00521718-77292022-11-0129118742875010.3390/curroncol29110688Feasibility Study and Clinical Impact of Incorporating Breast Tissue Density in High-Risk Breast Cancer Screening AssessmentAlison Rusnak0Shawna Morrison1Erika Smith2Valerie Hastings3Kelly Anderson4Caitlin Aldridge5Sari Zelenietz6Karen Reddick7Sonia Regnier8Ellen Alie9Nayaar Islam10Rutaaba Fasih11Susan Peddle12Erin Cordeiro13Eva Tomiak14Jean M. Seely15Inherited Cancer Program, Children’s Hospital of Eastern Ontario, 401 Smyth Road, Ottawa, ON K1H 8L1, CanadaRegional Genetics Program, Children’s Hospital of Eastern Ontario, Ottawa, ON K1H 8L1, CanadaRegional Genetics Program, Children’s Hospital of Eastern Ontario, Ottawa, ON K1H 8L1, CanadaRegional Genetics Program, Children’s Hospital of Eastern Ontario, Ottawa, ON K1H 8L1, CanadaRegional Genetics Program, Children’s Hospital of Eastern Ontario, Ottawa, ON K1H 8L1, CanadaRegional Genetics Program, Children’s Hospital of Eastern Ontario, Ottawa, ON K1H 8L1, CanadaRegional Genetics Program, Children’s Hospital of Eastern Ontario, Ottawa, ON K1H 8L1, CanadaThe High-Risk OBSP Program Nurse Navigator, The Ottawa Hospital, Ottawa, ON K1H 8L6, CanadaThe High-Risk OBSP Program Nurse Navigator, The Ottawa Hospital, Ottawa, ON K1H 8L6, CanadaPreviously High-Risk OBSP Program Screening Manager, The Ottawa Hospital, Ottawa, ON K1H 8L6, CanadaSchool of Epidemiology and Public Health, The Ottawa Hospital, University of Ottawa, Ottawa, ON K1N 6N5, CanadaDepartment of Radiology, The Ottawa Hospital, University of Ottawa, Ottawa, ON K1N 6N5, CanadaDepartment of Radiology, The Ottawa Hospital, University of Ottawa, Ottawa, ON K1N 6N5, CanadaDepartment of Surgery, University of Ottawa, Ottawa, ON K1N 6N5, CanadaDepartment of Genetics, Children’s Hospital of Eastern Ontario, University of Ottawa, Ottawa, ON K1N 6N5, CanadaDepartment of Radiology, The Ottawa Hospital, University of Ottawa, Ottawa, ON K1N 6N5, CanadaBreast tissue density (BTD) is known to increase the risk of breast cancer but is not routinely used in the risk assessment of the population-based High-Risk Ontario Breast Screening Program (HROBSP). This prospective, IRB-approved study assessed the feasibility and impact of incorporating breast tissue density (BTD) into the risk assessment of women referred to HROBSP who were not genetic mutation carriers. All consecutive women aged 40–69 years who met criteria for HROBSP assessment and referred to Genetics from 1 December 2020 to 31 July 2021 had their lifetime risk calculated with and without BTD using Tyrer-Cuzick model version 8 (IBISv8) to gauge overall impact. McNemar’s test was performed to compare eligibility with and without density. 140 women were referred, and 1 was excluded (<i>BRCA</i> gene mutation carrier and automatically eligible). Eight of 139 (5.8%) never had a mammogram, while 17/131 (13%) did not have BTD reported on their mammogram and required radiologist review. Of 131 patients, 22 (16.8%) were clinically impacted by incorporation of BTD: 9/131 (6.9%) became eligible for HROBSP, while 13/131 (9.9%) became ineligible (<i>p</i> = 0.394). It was feasible for the Genetics clinic to incorporate BTD for better risk stratification of eligible women. This did not significantly impact the number of eligible women while optimizing the use of high-risk supplemental MRI screening.https://www.mdpi.com/1718-7729/29/11/688breast screeninghigh-risk breast screeningdense breastssupplemental breast screeningbreast MRI |
| spellingShingle | Alison Rusnak Shawna Morrison Erika Smith Valerie Hastings Kelly Anderson Caitlin Aldridge Sari Zelenietz Karen Reddick Sonia Regnier Ellen Alie Nayaar Islam Rutaaba Fasih Susan Peddle Erin Cordeiro Eva Tomiak Jean M. Seely Feasibility Study and Clinical Impact of Incorporating Breast Tissue Density in High-Risk Breast Cancer Screening Assessment Current Oncology breast screening high-risk breast screening dense breasts supplemental breast screening breast MRI |
| title | Feasibility Study and Clinical Impact of Incorporating Breast Tissue Density in High-Risk Breast Cancer Screening Assessment |
| title_full | Feasibility Study and Clinical Impact of Incorporating Breast Tissue Density in High-Risk Breast Cancer Screening Assessment |
| title_fullStr | Feasibility Study and Clinical Impact of Incorporating Breast Tissue Density in High-Risk Breast Cancer Screening Assessment |
| title_full_unstemmed | Feasibility Study and Clinical Impact of Incorporating Breast Tissue Density in High-Risk Breast Cancer Screening Assessment |
| title_short | Feasibility Study and Clinical Impact of Incorporating Breast Tissue Density in High-Risk Breast Cancer Screening Assessment |
| title_sort | feasibility study and clinical impact of incorporating breast tissue density in high risk breast cancer screening assessment |
| topic | breast screening high-risk breast screening dense breasts supplemental breast screening breast MRI |
| url | https://www.mdpi.com/1718-7729/29/11/688 |
| work_keys_str_mv | AT alisonrusnak feasibilitystudyandclinicalimpactofincorporatingbreasttissuedensityinhighriskbreastcancerscreeningassessment AT shawnamorrison feasibilitystudyandclinicalimpactofincorporatingbreasttissuedensityinhighriskbreastcancerscreeningassessment AT erikasmith feasibilitystudyandclinicalimpactofincorporatingbreasttissuedensityinhighriskbreastcancerscreeningassessment AT valeriehastings feasibilitystudyandclinicalimpactofincorporatingbreasttissuedensityinhighriskbreastcancerscreeningassessment AT kellyanderson feasibilitystudyandclinicalimpactofincorporatingbreasttissuedensityinhighriskbreastcancerscreeningassessment AT caitlinaldridge feasibilitystudyandclinicalimpactofincorporatingbreasttissuedensityinhighriskbreastcancerscreeningassessment AT sarizelenietz feasibilitystudyandclinicalimpactofincorporatingbreasttissuedensityinhighriskbreastcancerscreeningassessment AT karenreddick feasibilitystudyandclinicalimpactofincorporatingbreasttissuedensityinhighriskbreastcancerscreeningassessment AT soniaregnier feasibilitystudyandclinicalimpactofincorporatingbreasttissuedensityinhighriskbreastcancerscreeningassessment AT ellenalie feasibilitystudyandclinicalimpactofincorporatingbreasttissuedensityinhighriskbreastcancerscreeningassessment AT nayaarislam feasibilitystudyandclinicalimpactofincorporatingbreasttissuedensityinhighriskbreastcancerscreeningassessment AT rutaabafasih feasibilitystudyandclinicalimpactofincorporatingbreasttissuedensityinhighriskbreastcancerscreeningassessment AT susanpeddle feasibilitystudyandclinicalimpactofincorporatingbreasttissuedensityinhighriskbreastcancerscreeningassessment AT erincordeiro feasibilitystudyandclinicalimpactofincorporatingbreasttissuedensityinhighriskbreastcancerscreeningassessment AT evatomiak feasibilitystudyandclinicalimpactofincorporatingbreasttissuedensityinhighriskbreastcancerscreeningassessment AT jeanmseely feasibilitystudyandclinicalimpactofincorporatingbreasttissuedensityinhighriskbreastcancerscreeningassessment |